Landmark TIOSPIRTM trial reinforces importance of SPIRIVA® in both available formulations as the world's leading maintenance therapy for chronic obstructive pulmonary disease (COPD)

Press/Media: Press / Media

PeriodNov 27 2017

Media coverage

1

Media coverage

  • TitleLandmark TIOSPIRTM trial reinforces importance of SPIRIVA® in both available formulations as the world's leading maintenance therapy for chronic obstructive pulmonary disease (COPD)
    Media name/outletBoehringer Ingelheim
    CountryUnited States
    Date11/27/17
    PersonsAntonio R Anzueto